Phosphatidic acid and lipid-sensing by mTOR

Trends in Endocrinology and Metabolism

Volumn 24, Issue 6, 2013, Pages 272-278

  Foster, David A ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

DG kinase; LPAAT; MTOR; Phosphatidic acid; Phospholipase D

Indexed keywords

DIACYLGLYCEROL KINASE; ESSENTIAL AMINO ACID; GLUCOSE; LYSOPHOSPHATIDIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE;

BIOSYNTHESIS; CATALYSIS; CELL CYCLE PROGRESSION; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; HUMAN; HYDROLYSIS; METABOLITE; NONHUMAN; NUTRIENT CONTENT; PRIORITY JOURNAL; REVIEW;

ACYLTRANSFERASES; ANIMALS; DIACYLGLYCEROL KINASE; HUMANS; PHOSPHATIDIC ACIDS; PHOSPHOLIPASE D; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84878252749     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2013.02.003     Document Type: Review

References (74)

1. Polak P., Hall M.N. mTOR and the control of whole body metabolism. Curr. Opin. Cell Biol. 2009, 21:209-218.
2. Wullschleger S., et al. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
3. Sengupta S., et al. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell 2010, 40:310-322.
4. Avruch J., et al. Amino acid regulation of TOR complex 1. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E592-E602.
5. Fang Y., et al. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001, 294:1942-1945.
6. Foster D.A. Regulation of mTOR by phosphatidic acid?. Cancer Res. 2007, 67:1-4.
7. Sun Y., Chen J. mTOR signaling: PLD takes center stage. Cell Cycle 2008, 7:3118-3123.
8. Toschi A., et al. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol. Cell. Biol. 2009, 29:1411-1420.
9. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
10. Foster D.A. Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. Biochim. Biophys. Acta 2009, 1791:949-955.
11. Zetterberg A., et al. What is the restriction point?. Curr. Opin. Cell Biol. 1995, 7:835-842.
12. Foster D., et al. Regulation of G1 cell cycle progression: distinguishing the restriction point from a nutrient-sensing cell growth checkpoint(s). Genes Cancer 2010, 1:1124-1131.
13. Fingar D.C., et al. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 2004, 24:200-216.
14. Gadir N., et al. Defective TGF-beta signaling sensitizes human cancer cells to rapamycin. Oncogene 2008, 27:1055-1062.
15. Ward P.S., et al. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012, 21:297-308.
16. Blagosklonny M.V. Molecular damage in cancer: an argument for mTOR-driven aging. Aging 2011, 3:1130-1141.
17. Hardt M., et al. Activating mutations of TOR (target of rapamycin). Genes Cells 2011, 16:141-151.
18. Leto D., Saltiel A.R. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat. Rev. Mol. Cell Biol. 2012, 13:383-396.
19. Warburg O. On respiratory impairment in cancer cells. Science 1956, 124:269-270.
20. Cantor J.R., Sabatini D.M. Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2012, 2:881-898.
21. Chen Y., et al. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 2003, 22:3937-3942.
22. Dall'Armi C., et al. The phospholipase D1 pathway modulates macroautophagy. Nat. Commun. 2010, 1:142.
23. Thielmann I., et al. Redundant functions of phospholipases D1 and D2 in platelet alpha-granule release. J. Thromb. Haemost. 2012, 10.1111/j.1538-7836.2012.04924.x.
24. Guertin D., et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1. Dev. Cell 2006, 11:859-871.
25. Gangloff Y.G., et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol. Cell. Biol. 2004, 24:9508-9516.
26. Athenstaedt K., Daum G. Phosphatidic acid, a key intermediate in lipid metabolism. Eur. J. Biochem. 1999, 266:1-16.
27. Wendel A.A., et al. Glycerol-3-phosphate acyltransferases: rate limiting enzymes of triacylglycerol biosynthesis. Biochim. Biophys. Acta 2009, 1791:501-506.
28. Rincon E., et al. Diacylglycerol kinase ζ: at the crossroads of lipid signaling and protein complex organization. Prog. Lipid Res. 2012, 51:1-10.
29. Merida I., et al. Diacylglycerol kinases: at the hub of cell signalling. Biochem. J. 2008, 409:1-18.
30. Tang W., et al. Identification of a novel human lysophosphatidic acid acyltransferase, LPAAT-theta, which activates mTOR pathway. J. Biochem. Mol. Biol. 2006, 39:626-635.
31. Avila-Flores A., et al. Modulation of the mammalian target of rapamycin pathway by diacylglycerol kinase-produced phosphatidic acid. J. Biol. Chem. 2005, 280:10091-10099.
32. Takita T., et al. Diacylglycerol kinase inhibitor R59022-induced autophagy and apoptosis in the neuronal cell line NG108-15. Arch. Biochem. Biophys. 2011, 509:197-201.
33. Gorentla B., et al. Negative regulation of mTOR activation by diacylglycerol kinases. Blood 2011, 117:4022-4031.
34. Coon M., et al. Inhibition of lysophosphatidic acid acyltransferase beta disrupts proliferative and survival signals in normal cells and induces apoptosis of tumor cells. Mol. Cancer Ther. 2003, 2:1067-1078.
35. Bobrovnikova-Marjon E., et al. PERK utilizes intrinsic lipid kinase activity to generate phosphatidic acid, mediate Akt activation, and promote adipocyte differentiation. Mol. Cell. Biol. 2012, 32:2268-2278.
36. Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell Biol. 2012, 13:89-102.
37. Ozcan U., et al. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol. Cell 2008, 29:541-551.
38. DeBerardinis R.J., et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7:11-20.
39. DeBerardinis R.J., et al. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 2008, 18:54-61.
40. Toschi A., et al. Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells. Cancer Lett. 2010, 299:72-79.
41. Christofk H.R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
42. Hitosugi T., et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2009, 2:ra73.
43. Vander Heiden M.G., et al. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
44. Possemato R., et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011, 476:346-350.
45. Gruning N.M., et al. Pyruvate kinase triggers a metabolic feedback loop that controls redox metabolism in respiring cells. Cell Metab. 2011, 14:415-427.
46. Russo G.L. Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem. Pharmacol. 2009, 77:937-946.
47. Sardesai V.M. The essential fatty acids. Nutr. Clin. Pract. 1992, 7:179-186.
48. Zhang C., et al. Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signaling. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:1667-1672.
49. Yoon M.S., et al. Phosphatidic acid activates mammalian target of rapamycin complex 1 (mTORC1) kinase by displacing FK506 binding protein 38 (FKBP38) and exerting an allosteric effect. J. Biol. Chem. 2011, 286:29568-29574.
50. Xu L., et al. Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1). J. Biol. Chem. 2011, 286:25477-25486.
51. Yoon M.S., et al. Class III PI-3-kinase activates phospholipase D in an amino acid-sensing mTORC1 pathway. J. Cell Biol. 2011, 195:435-447.
52. Veverka V., et al. Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. Oncogene 2008, 27:585-595.
53. Rodriguez Camargo D.C., et al. The FKBP-rapamycin binding domain of human TOR undergoes strong conformational changes in the presence of membrane mimetics with and without the regulator phosphatidic acid. Biochemistry 2012, 51:4909-4921.
54. Bjorklund M., et al. Identification of pathways regulating cell size and cell-cycle progression by RNAi. Nature 2006, 439:1009-1013.
55. Ray S., et al. Phospholipase D controls Dictyostelium development by regulating G protein signaling. Cell. Signal. 2011, 23:335-343.
56. Rosel D., et al. TOR complex 2 (TORC2) in Dictyostelium suppresses phagocytic nutrient capture independently of TORC1-mediated nutrient sensing. J. Cell Sci. 2012, 125:37-48.
57. Ghosh S., et al. Functional analysis of a phosphatidic acid binding domain in human Raf-1 kinase: mutations in the phosphatidate binding domain lead to tail and trunk abnormalities in developing zebrafish embryos. J. Biol. Chem. 2003, 278:45690-45696.
58. Goi T., et al. An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity. EMBO J. 2000, 19:623-630.
59. Jiang H., et al. Involvement of Ral GTPase in v-Src-induced phospholipase D activation. Nature 1995, 378:409-412.
60. Maehama T., et al. RalA functions as an indispensable signal mediator for the nutrient-sensing system. J. Biol. Chem. 2008, 283:35053-35059.
61. Wiczer B.M., Thomas G. Phospholipase D and mTORC1: nutrients are what bring them together. Sci. Signal. 2012, 5:pe13.
62. Zhong M., et al. Phospholipase D prevents apoptosis in v-Src-transformed rat fibroblasts and MDA-MB-231 breast cancer cells. Biochem. Biophys. Res. Commun. 2003, 302:615-619.
63. Chen Y., et al. Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene 2005, 24:672-679.
64. Rodrik V., et al. Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc. Mol. Cell. Biol. 2005, 25:7917-7925.
65. Rodrik V., et al. Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells. FEBS Lett. 2006, 580:5647-5652.
66. Hui L., et al. mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells. J. Biol. Chem. 2005, 280:35829-35835.
67. Zheng Y., et al. Phospholipase D couples survival and migration signals in stress response of human cancer cells. J. Biol. Chem. 2006, 281:15862-15868.
68. Shi M., et al. Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. Cancer Lett. 2007, 258:268-275.
69. Garcia A., et al. Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin. Cancer Res. 2008, 14:4267-4274.
70. Wolf I., et al. Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. Int. J. Oncol. 2007, 30:1529-1537.
71. Lavieri R.R., et al. Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor. J. Med. Chem. 2010, 53:6706-6719.
72. Lewis J.A., et al. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity. Bioorg. Med. Chem. Lett. 2009, 19:1916-1920.
73. Lavieri R., et al. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity. Bioorg. Med. Chem. Lett. 2009, 19:2240-2243.
74. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7:763-777.